Description

Technical Parameters

Tacrolimus CAS 104987-11-3 is strong-efficacy macrolide immunosuppressant. At the molecular level, its effect is mediated through protein FKBP12 in cytoplasm which is binding with it. FKBP12 makes Tacrolimus into cell and form a complex that competitively binds specifically to calmodulin and inhibits calmodulin (the latter mediates calcium-dependent inhibitory signal transduction system in T-cells), so as to block a series Gene transcription of lymphokine. In-vitro experiments demonstrate that Tacrolimus is strong-efficacy immunosuppressant, it can inhibit formation of cytotoxic lymphocytes, and allograft rejection is mainly caused by the latter.

Tacrolimus CAS 104987-11-3

Product: Tacrolimus CAS 104987-11-3

Alternative Names: FK506; Prograf; Advagraf; Astagraf XL; Envarsus XR; Tacrolimus; CAS 104987-11-3; Tacrolimus API; Advagraf API; Protopic API;

Chemical Name: (3S, 4R, 5S, 8R, 9E, 12S, 14S, 15R, 16S, 18R, 19R, 26aS)-5, 6, 8, 11, 12, 13, 14, 15, 16, 17, 18, 19, 24, 25, 26, 26a-Hexadecahydro-5, 19-dihydroxy-3-{(1E)-2-[(1R, 3R, 4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethenyl}-14, 16-dimethoxy-4, 10, 12, 18-tetramethyl-8-(2-propenyl)-15, 19-epoxy-3H-pyrido[2, 1-c][1, 4]oxaazacyclotricosine-1, 7, 20, 21 (4H, 23H)-tetrone.

Molecular formula: C₄₄H₆₉NO₁₂S
Molecular mass: 804.02
CAS No.: 104987-11-3

Biological activity: Tacrolimus exhibits significant biological activity, primarily as an immunosuppressive agent. Its main mechanism of action is the inhibition of T-cell activation, which plays a crucial role in the immune response.

This drug inhibits activation of T-cells, TH-cell-dependent B-cells-propagation, and generation of lymphokine such as express of interleukin 2, interleukin 3, β-interferon and interleukin 2 receptor. Tacrolimus can inhibit allograft rejection of skin, heart, kidney and liver, extend survival time of allograft, and this is evidenced in bodies of rodent, dogs, primate and human. It has been widely used for acute and chronic rejection of liver, kidney and bone marrow transplantation.

1. Payment term

TT, LC

2. Delivery date

Negotiable

3. Market

Middle East / Africa / Asia / South America / Europe

4. Sample

Available
5. Executive standards
CP, EP, USP

6. Qualification certificate

Registration of "A" status, Chinese GMP; WC license, COPP certificate, CEP certificate, US DMF registration number; MFDS Registration Certificate

7. Packaging size specification

Inner package: single-layers polyethylene bag and aluminum foil bag.

Outer package: Medicinal aluminum bottle.

Packaging size: 500 g/bottle.

Our Advantage

We have branch offices in Dubai and India

we have own reliable & Long-term cooperative & experienced factory

Variety products for selection from China and India

We can customize according to your requirements

We can do OEM & ODM

We can offer N-1 to API

Tacrolimus CAS 104987-11-3 API FAQ

Q: What is Tacrolimus?

A: Tacrolimus is an immunosuppressive medication used to prevent organ rejection in transplant recipients. It is also prescribed for certain autoimmune diseases such as eczema (atopic dermatitis) and in the treatment of graft-versus-host disease (GVHD) after bone marrow transplantation.

Q: How does Tacrolimus work?

A: Tacrolimus works by suppressing the immune system. It inhibits the activation of T-cells, which are involved in immune responses. By blocking T-cell activation, Tacrolimus helps prevent the immune system from attacking transplanted organs or causing damage in autoimmune conditions.

Q: What types of transplant rejection does Tacrolimus prevent?

A: Tacrolimus is commonly used to prevent rejection in organ transplant recipients, including kidney, liver, heart, and lung transplants. It is typically used in combination with other immunosuppressive medications.

Q: What are the potential side effects of Tacrolimus?

A: Common side effects of Tacrolimus can include increased susceptibility to infections, high blood pressure, tremors, increased blood sugar levels, kidney problems, and gastrointestinal disturbances. Long-term use may also be associated with an increased risk of developing certain types of cancer.

Q: Are there any drug interactions with Tacrolimus?

A: Yes, Tacrolimus can interact with various medications.

Q: How is Tacrolimus monitored during treatment?

A: Tacrolimus levels in the blood are closely monitored through blood tests to ensure that the drug is within the therapeutic range and to prevent toxicity or inadequate immunosuppression. Regular monitoring of kidney function, blood pressure, and other relevant parameters is also necessary.

Q: Can Tacrolimus be used during pregnancy or breastfeeding?

A: Tacrolimus should be used with caution during pregnancy and breastfeeding.

Hot Tags: tacrolimus cas 104987-11-3, China tacrolimus cas 104987-11-3 manufacturers, suppliers, factory, api for human network data, intermediate nitro compounds, intermediate diastereomers, api for human device usage data, api for human communication data, api for human performance data